What is the recommended acute and long‑term management for a patient with acute deep‑vein thrombosis (DVT) and pulmonary embolism (PE), including anticoagulant choice, dosing, contraindications, and duration of therapy?

Management of Deep Vein Thrombosis and Pulmonary Embolism

Immediate Anticoagulation Strategy

For patients with acute DVT or PE without hemodynamic instability, initiate a direct oral anticoagulant (DOAC)—specifically apixaban, rivaroxaban, dabigatran, or edoxaban—immediately upon diagnosis, as these are superior to vitamin K antagonists (VKAs) and do not require parenteral bridging in most cases. 1

High-Risk PE (Hemodynamically Unstable)

• Administer unfractionated heparin (UFH) with weight-adjusted bolus immediately without waiting for diagnostic confirmation if clinical suspicion is high 1
• Systemic thrombolytic therapy is mandatory for patients with systolic blood pressure <90 mmHg or cardiogenic shock 1
• If thrombolysis is contraindicated or fails, proceed directly to surgical pulmonary embolectomy 1
• Percutaneous catheter-directed treatment is an alternative when surgery is unavailable or thrombolysis has failed 1
• Support with norepinephrine and/or dobutamine for hemodynamic stabilization 1

Intermediate- and Low-Risk PE/DVT

Preferred initial anticoagulation options (in order):

1. Apixaban or rivaroxaban (no parenteral lead-in required) 1, 2

   • Apixaban: 10 mg twice daily × 7 days, then 5 mg twice daily 3
   • Rivaroxaban: 15 mg twice daily × 21 days, then 20 mg once daily 1

2. Dabigatran or edoxaban (require 5-10 days parenteral anticoagulation first) 1

3. Low-molecular-weight heparin (LMWH) or fondaparinux preferred over UFH for parenteral therapy 1

4. VKA (warfarin) only if DOACs contraindicated:

   • Start simultaneously with parenteral anticoagulation on day 1 2
   • Continue parenteral therapy minimum 5 days AND until INR ≥2.0 for 24 hours 1, 2
   • Target INR 2.5 (range 2.0-3.0) 1, 2

Critical contraindications to DOACs:

• Severe renal impairment (CrCl <30 mL/min for most DOACs) 1
• Antiphospholipid antibody syndrome (use VKA instead) 1, 2
• Pregnancy and lactation (use LMWH) 1

---

Duration of Anticoagulation: Algorithmic Approach

Minimum Treatment for ALL Patients

Continue therapeutic anticoagulation for at least 3 months regardless of VTE etiology 1, 2

After 3 Months: Decision Algorithm

1. Provoked VTE by major transient/reversible risk factor (surgery):

• STOP anticoagulation at 3 months 1, 2

2. Provoked VTE by minor transient risk factor (immobilization, estrogen, minor trauma):

• STOP anticoagulation at 3 months in most patients 1, 2
• Consider 6 months if bleeding risk is low 1

3. Unprovoked VTE (no identifiable trigger):

• Continue indefinitely (no scheduled stop date) if low-to-moderate bleeding risk 1, 2
• STOP at 3 months only if high bleeding risk 1

4. VTE with persistent risk factor (active cancer, chronic immobility, thrombophilia):

• Continue indefinitely 1, 2

5. Recurrent VTE (≥2 episodes):

• Continue indefinitely regardless of bleeding risk (strong recommendation) 1, 2

---

Special Populations

Cancer-Associated Thrombosis

• Prefer oral factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) over LMWH for both initial and extended treatment 2
• Avoid edoxaban and rivaroxaban in luminal GI malignancies due to increased bleeding risk; use apixaban or LMWH instead 2
• Continue anticoagulation as long as cancer is active 1

Antiphospholipid Syndrome

• Use VKA (target INR 2.5) instead of DOACs due to higher thrombosis risk with DOACs 2
• Continue indefinitely 1

Pregnancy

• LMWH is the only safe option throughout pregnancy and postpartum 1
• DOACs and VKAs are absolutely contraindicated 1

---

Inferior Vena Cava (IVC) Filters

IVC filters are NOT routinely recommended 1

Only indication: Absolute contraindication to anticoagulation (active bleeding, recent neurosurgery, severe bleeding diathesis) 1

• Do NOT place filters in addition to anticoagulation 1, 2
• If filter placed due to temporary contraindication, start anticoagulation as soon as bleeding risk resolves 1

---

Thrombolysis: When to Use

Systemic thrombolysis indications:

• High-risk PE with hemodynamic instability (systolic BP <90 mmHg) 1
• Intermediate-risk PE with clinical deterioration despite anticoagulation (rescue therapy) 1

Do NOT use thrombolysis for:

• Routine intermediate-risk PE without deterioration 1
• Low-risk PE 1
• Acute DVT without PE 1

Preferred administration: Peripheral vein infusion over 2 hours (not catheter-directed) 1

---

Treatment Setting and Mobility

• Treat uncomplicated DVT and low-risk PE in outpatient setting when home circumstances are adequate 2, 4
• Early ambulation is preferred over bed rest for DVT patients 2
• Hospitalize only for high-risk or intermediate-risk PE, severe symptoms, or inadequate home support 4

---

Critical Pitfalls to Avoid

1. Never delay anticoagulation while awaiting diagnostic confirmation if clinical probability is intermediate or high 1

2. Never use DOACs in antiphospholipid syndrome—this increases thrombosis risk 1, 2

3. Never stop anticoagulation before 3 months except for major bleeding 1, 2

4. Never place IVC filters routinely—only when anticoagulation is absolutely contraindicated 1, 2

5. Never use thrombolysis for stable intermediate-risk or low-risk PE—bleeding risk outweighs benefit 1

6. Never use UFH when LMWH is available unless patient has severe renal failure (CrCl <30 mL/min), hemodynamic instability, or high bleeding risk requiring rapid reversibility 1

7. Never forget to reassess bleeding risk and renal function at regular intervals during extended anticoagulation 1